Reader TTS

Adding an oncolytic virus to classic immune checkpoint inhibition elicits treatment responses and survival benefit for select immunologically ‘cold’ recurrent glioblastomas, although

creative treatment strategies are still needed for patients with highly anti-inflammatory tumors. Access through your institution Buy or subscribe This is a preview of subscription content,

access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99

/ 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on

SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about

institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Reardon, D. A. et al. _JAMA Oncol._ 6, 1003–1010 (2020). Article  PubMed  Google Scholar  * Lim, M. et al.

_Neuro Oncol._ 24, 1935–1949 (2022). Article  CAS  PubMed  PubMed Central  Google Scholar  * Omuro, A. et al. _Neuro Oncol._ 25, 123–134 (2023). Article  PubMed  Google Scholar  * Nassiri,

F. et al. _Nat. Med._ https://doi.org/10.1038/s41591-02347-y (2023). Article  PubMed  Google Scholar  * Moehler, M. H. et al. _Hum. Gene Ther._ 16, 996–1005 (2005). Article  CAS  PubMed 

Google Scholar  * Lang, F. F. et al. _J. Clin. Oncol._ 36, 1419–1427 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Ribas, A. et al. _Cell_ 170, 1109–1119 (2017). Article 

CAS  PubMed  PubMed Central  Google Scholar  * Lu, Y. et al. _Nat. Commun._ 12, 4031 (2021). Article  CAS  PubMed  PubMed Central  Google Scholar  * Vogelbaum, M. A. et al. _Neuro Oncol._

22, 1568–1579 (2020). Article  PubMed  PubMed Central  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Neurosurgery, Stanford University

School of Medicine, Stanford, CA, USA Adela Wu & Michael Lim Authors * Adela Wu View author publications You can also search for this author inPubMed Google Scholar * Michael Lim View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Michael Lim. ETHICS DECLARATIONS COMPETING INTERESTS M.L. receives

research support from Arbor, BMS, Accuray, Biohaven and Urogen; is a research consultant for VBI, InCephalo Therapeutics, Merck, Pyramid Bio, Insightec, Biohaven, Sanianoia, Hemispherian,

Novocure, Noxxon, InCando, Century Therapeutics, CraniUs, MediFlix and XSense; is a shareholder of Egret Therapeutics; has patents for focused radiation plus checkpoint inhibitors, local

chemotherapy plus checkpoint inhibitors, and checkpoints for neuro-inflammation; is a non-research consultant for Stryker; and is on the Data Safety and Monitoring Board for Cellularity.

RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Wu, A., Lim, M. Advancing combination therapy for recurrent glioblastoma. _Nat Med_ 29, 1318–1319 (2023).

https://doi.org/10.1038/s41591-023-02350-3 Download citation * Published: 15 May 2023 * Issue Date: June 2023 * DOI: https://doi.org/10.1038/s41591-023-02350-3 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative